OWC Pharmaceutical Research Corp. to Collaborate with Sourasky Medical Center in Tel Aviv for a Safety Study on Its Cannabis-Based Tablets

Tel Aviv Sourasky Medical Center will conduct a safety and
tolerability trial on OWC’s sublingual tablets for the treatment of
chronic low back pain

RAMAT GAN, Israel–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/TLV?src=hash" target="_blank"gt;#TLVlt;/agt;–OWC
Pharmaceutical Research Corp. (OTCQB: OWCP) (http://owcpharma.com/),
the company transforming cannabis into scientifically proven and
clinically approved medical solutions, announces an agreement with the
Tel Aviv Sourasky Medical Center Fund.

The medical center will perform a single-dose, randomized crossover
study to compare the safety, tolerability, and pharmacokinetics of OWC’s
tablet with Buccal Sativex in healthy adult volunteers. The tablet is
designed to provide rapid API uptake through buccal membranes and to be
a substitute for patients being treated with medical cannabis by smoking.

OWC Pharmaceutical Research Corp. is focusing its efforts on developing
cannabis-based therapeutic products and treatments, specifically
designed for several medical conditions and diseases. The company’s
solutions include a topical ointment to treat skin diseases, such as
psoriasis, a sublingual disintegrating tablet to treat chronic pain, and
a unique formulation aimed at treating multiple Myeloma, a cancer of the
plasma cells found in bone marrow.

“There is a very large amount of hype surrounding medical applications
of cannabis, but we are one of the few companies doing real medical
research,” says Mordechai Bignitz, CEO of OWC Pharmaceutical Research
Corp. “Our collaboration with Sourasky Medical Center is further proof
of our commitment to developing real cannabis-based medical solutions.”

About OWC Pharmaceutical Research Corp.:
OWC Pharmaceutical
Research Corp. conducts medical research and clinical trials to develop
cannabis-based pharmaceuticals and treatments for conditions including
multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWCP is
also developing unique and effective delivery systems and dosage forms
of medical cannabis.

Notice Regarding Forward-Looking Statements
This news
release contains “forward-looking statements” as that term is defined in
Section 27A of the United States Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended.
Statements in this press release, which are not purely historical, are
forward-looking statements and include any statements regarding beliefs,
plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, filing patent
applications, product development, and business strategy. Actual results
could differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, the inherent
uncertainties associated with new projects and development stage
companies. These forward-looking statements are made as of the date of
this news release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual results
could differ from those projected in the forward-looking statements.
Although we believe that any beliefs, plans, expectations and intentions
contained in this press release are reasonable, there can be no
assurance that any such beliefs, plans, expectations or intentions will
prove to be accurate. Investors should consult all of the information
set forth herein and should also refer to the risk factors disclosure
outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic
reports filed from time-to-time with the Securities and Exchange
Commission.

Contacts

Company Media Contact:
Ilit Gluska
Blonde 2.0 for OWC Pharma
[email protected]
+972-55-8895272